Kyverna Therapeutics
About Kyverna Therapeutics
KYVERNA is pioneering a new class of treatments and potential cures for serious autoimmune diseases. The company's therapeutic platform combines advanced T-cell engineering and synthetic biology technologies to suppress and eliminate the autoreactive immune cells at the root cause of inflammatory diseases.
Open positions (10)
Medical Director/Sr. Medical Director, Clinical Development
Head of Information Technology
Medical Science Liaison/Senior Medical Science Liaison - (Great Lakes)
Medical Science Liaison/Senior Medical Science Liaison - (Ohio Valley)
Regulatory Affairs, Consultant
Regulatory Affairs, Consultant
Head of Information Technology
Executive Director, Medical Writing
Medical Science Liaison/Senior Medical Science Liaison - (Southcentral)
Medical Director/Sr. Medical Director, Clinical Development
Company details
Funding
Total raised
$322M
Last stage
Public
Investors
Founders
Jeffrey Greve
Co-founder of Kyverna Therapeutics (formerly BAIT Therapeutics), a clinical-stage cell therapy company focused on autoimmune diseases.
Dominic Borie
MD, PhD immunologist and digestive tract/liver transplant surgeon. Appointed founding CEO of Kyverna in 2020; subsequently served as President of R&D. Previously VP at Horizon Therapeutics and held leadership roles at Genentech, Amgen, and Roche.
LinkedInWhat happens next.
No applications, no recruiter spam. Just the intro.
Confirm the fit
A few questions to make sure this role is the right shape for you. Two minutes.
I pitch you to the company
I write the intro, send it to the founder, and handle the back-and-forth.
A meeting lands on your calendar
If they’re a yes, I book the chat. You show up — that’s the whole job-hunt.